Epigenetics suggests new perspectives for the treatment of polycystic ovary syndrome: Transgenerational effect of fetal exposure to Antimüllerian Hormone

Michel Pugeat; Didier Dewailly

doi:10.1016/j.ando.2021.04.001

Epigenetics suggests new perspectives for the treatment of polycystic ovary syndrome: Transgenerational effect of fetal exposure to Antimüllerian Hormone

Ann Endocrinol (Paris). 2021 Apr;82(2):71-73. doi: 10.1016/j.ando.2021.04.001. Epub 2021 Apr 8.

Authors

Michel Pugeat¹, Didier Dewailly²

Affiliations

¹ Inserm U1060, INRA U1397, université de Lyon, laboratoire Carmen, université Claude-Bernard Lyon 1, INSA-Lyon, faculté de médecine Lyon-Sud, 69600 Oullins, France. Electronic address: michel.pugeat@chu-lyon.fr.
² Faculty of Medicine, University of Lille, INSERM: Laboratory of Development and Plasticity of the Neuroendocrine Brain, Jean-Pierre Aubert Research Centre, UMR-S 1172, Lille, France. Electronic address: didier.dewailly@orange.fr.

PMID: 33839124
DOI: 10.1016/j.ando.2021.04.001

No abstract available

Keywords: Androgens; Androgènes; Anti-mullerian hormone; Effets transgénérationnels; Epigenetics; Hormone anti-mullérienne; Polycyctic ovary syndrome; Syndrome des ovaires polykystiques; Épigénétique.

Publication types

Editorial

MeSH terms

Animals
Anti-Mullerian Hormone / adverse effects*
Anti-Mullerian Hormone / blood
Epigenesis, Genetic / genetics*
Female
Fetus / drug effects
Humans
Maternal-Fetal Exchange
Polycystic Ovary Syndrome / genetics*
Polycystic Ovary Syndrome / physiopathology
Pregnancy

Substances

Anti-Mullerian Hormone